American Journal of Hematology最新文献

{"title":"Clinical Factors Associated With Catheter-Related VTE in Patients Undergoing Hematopoietic Cell Transplantation: A Multi-Center Study.","authors":"Navel Gopal Subramanian,Danielle Guffey,Jonathan Avery,David Garcia,Ryan Basom,Stephanie J Lee,Katherine Klein,Partow Kebriaei,Gabriela Rondon,Elizabeth Shpall,Shida Jin,Elliana Young,Cristhiam Mauricio Rojas Hernandez,Ang Li","doi":"10.1002/ajh.27720","DOIUrl":"https://doi.org/10.1002/ajh.27720","url":null,"abstract":"","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"17 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144065796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Mutational Landscape in Polycythemia Vera: Phenotype, Genotype, and Prognostic Correlates.","authors":"Masooma S Rana,Moazah Iftikhar,Yamna Jadoon,Maymona Abdelmagid,David S Viswanatha,Rong He,Kaaren K Reichard,Animesh D Pardanani,Naseema Gangat,Ayalew Tefferi","doi":"10.1002/ajh.27717","DOIUrl":"https://doi.org/10.1002/ajh.27717","url":null,"abstract":"Polycythemia vera (PV) is invariably associated with a JAK2 mutation, with over 50% of patients harboring additional non-JAK2 mutations. In the current study, 319 patients with PV underwent NGS at diagnosis or in chronic phase PV (Group A: N = 270, 85%) or at the time of fibrotic (Group B; N = 37, 12%) or leukemic (Group C; N = 12, 4%) transformation. Mutational frequencies involving TP53/SRSF2/IDH1/U2AF1 were significantly (p < 0.05) different between patients in the mutually exclusive Groups A (2%/4%/2%/0.4%), B (8%/0%/0%/5%), and C (50%/25%/17%/8%). Analyses on phenotype/genotype associations and prognostic impact on overall (OS), leukemia-free (LFS), and myelofibrosis-free (MFFS) survival were limited to Group A patients. ASXL1MUT was associated with younger age (p < 0.01), SRSF2MUT with older age and leukocytosis (p < 0.01), and TP53MUT with leukocytosis (p < 0.01). Mutation co-segregation was apparent between ASXL1 and IDH2 (p < 0.01) or SRSF2 (p < 0.01), SRSF2 and IDH2 (p < 0.01), and TP53 and NRAS (p = 0.01). Multivariable analysis identified SRSF2MUT (p < 0.01; HR, 4.2, 1.9-9.5), IDH2MUT (p = 0.01; HR, 5.3, 1.8-15.3), ASXL1MUT (p = 0.04; HR, 2.0, 1.1-3.7), leukocyte count ≥ 15 × 109/L (p < 0.01; HR 2.0, 1.3-3.1), and advanced age (p < 0.01) as risk factors for OS. Median OS in the presence (N = 235; 87%) or absence (N = 35; 13%) of any adverse mutation (i.e., SRSF2MUT, ASXL1MUT, or IDH2MUT) was 8.8 versus 17.8 years (p = 0.01; HR 1.8, 1.1-2.9). In addition, ASXL1MUT (p = 0.02; HR, 1.6-24.9), SRSF2MUT (p = 0.06; HR, 11.9, 1.1-126.2), and advanced age (p = 0.04) were associated with inferior LFS, and SRSF2MUT (p < 0.01; HR, 24.0, 5.5-103.8) and abnormal karyotype (p < 0.01; HR 3.8, 1.6-8.9) with inferior MFFS. The number of non-JAK2 mutations was significant in predicting outcome in univariate but not multivariable analysis. The observations from the current study highlight the prognostic significance of non-JAK2 mutations in PV and the prospect of their inclusion in future prognostic models.","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"129 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143992001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub-Study of the FOLL12 Trial.","authors":"Rexhep Durmo,Stephane Chauvie,Carla Minoia,Fabrizio Bergesio,Federico Fallanca,Simona Peano,Luigi Marcheselli,Antonella Anastasia,Carola Boccomini,Paolo Corradini,Jacopo Olivieri,Luca Arcaini,Federica Cavallo,Adalberto Ibatici,Luca Nassi,Vittoria Tarantino,Antonello Pinto,Caterina Stelitano,Alessandro Pulsoni,Francesca Ricci,Salvatrice Mancuso,Emanuele Cencini,Nicola Di Renzo,Clara Mannarella,Angelo Palmas,Pierluigi Zinzani,Caterina Bocci,Francesca Rossi,Angelo Michele Carella,Massimo Federico,Annibale Versari,Luca Guerra,Stefano Luminari","doi":"10.1002/ajh.27711","DOIUrl":"https://doi.org/10.1002/ajh.27711","url":null,"abstract":"Discordant results have been generated regarding the prognostic role of Total Metabolic Tumor Volume (TMTV) in Follicular Lymphoma (FL). The use of prospective data and the adoption of the newly defined standardized SUV4 method for calculating TMTV may generate stronger evidence. We conducted a pre-planned post hoc analysis of the prospective multicenter randomized phase III FOLL12 trial for newly diagnosed high tumor burden FL (grade 1-3a), which mandated baseline staging with PET. Baseline PET/CT scans were reviewed centrally, and TMTV was calculated using the fixed threshold of SUV4. Kaplan-Meier and Cox regression were used for survival analysis. The primary study endpoint was Progression free Survival (PFS). A total of 689 FL patients were available for TMTV definition. Median TMTV was 161 mL (IQR 50 to 388 mL) and the best cutoff value was set at 180 mL. Patients with high TMTV had a significantly lower 5-year PFS compared to those with low TMTV: 59% (95% CI, 53-65%) vs. 74% (95% CI, 69-78%) HR 1.61 (95% CI, 1.24-2.09). Prognostic role of TMTV was independent of study arm, chemotherapy regimen, and FLIPI2. Combined with FLIPI-2, we identified three groups with different 5-yr PFS rates, with the lowest rates (51%) for patients with high TMTV and high FLIPI2. Combined TMTV and FLIPI model was also prognostic to predict the risk of early progression and of death. Applying the SUV4 standard method pre-treatment TMTV is confirmed as a strong and independent predictor of PFS in FL patients. Integrating TMTV with FLIPI-2 improves risk assessment.","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"81 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143945383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline Hemoglobin Values and Clinical Outcomes in Acute Venous Thromboembolism: Insights From the RIETE Registry","authors":"Carmine Siniscalchi, Pierpaolo Di Micco, Antonella Tufano, Maria Luisa Peris, Patricia López-Miguel, Alicia Alda-Lozano, Pilar Llamas, Diego Durán Barata, Yaser Jenab, Manuel Monreal","doi":"10.1002/ajh.27707","DOIUrl":"https://doi.org/10.1002/ajh.27707","url":null,"abstract":"&lt;p&gt;Venous thromboembolism (VTE) is a major global health concern and a leading cause of morbidity and mortality. While anticoagulation effectively reduces the risk of recurrent VTE, it is associated with an inherent risk of bleeding. Identifying patient characteristics that influence these risks is critical for personalized management. Baseline hemoglobin (Hb) values have emerged as a potential prognostic marker [&lt;span&gt;1-5&lt;/span&gt;], reflecting both underlying comorbidities and hemostatic alterations. However, the impact of Hb values on both thrombotic and bleeding complications in anticoagulated VTE patients remains insufficiently characterized.&lt;/p&gt;\u0000&lt;p&gt;We analyzed data from 111,646 patients with acute VTE included in the RIETE registry, a large multinational prospective cohort (ClinicalTrials.gov identifier: NCT02832245) [&lt;span&gt;6&lt;/span&gt;]. Patients were stratified into Hb quintiles: &lt; 11.4, 11.4–12.6, 12.7–13.6 (reference), 13.7–14.7, and &gt; 14.7 g/dL. We assessed 90-day rates of recurrent VTE, major bleeding, arterial ischemic events (myocardial infarction, ischemic stroke, or limb amputation), and all-cause mortality. Multivariable logistic regression models were adjusted for demographic and clinical characteristics, including VTE risk factors, initial VTE presentation, comorbidities, renal function, leukocyte and platelet counts, anticoagulant strategy, and concomitant medications.&lt;/p&gt;\u0000&lt;p&gt;Patients with lower Hb values were more likely to be female (64%), older, and have a lower body mass index, while those in the highest Hb quintile were predominantly male (81%) and younger. The initial presentation of VTE varied, with presentation as PE becoming more frequent with increasing Hb values, whereas upper-limb DVT was more prevalent in the lowest Hb group (&lt; 11.4 g/dL). Comorbidities such as active cancer, chronic heart failure, renal failure, and prior ischemic stroke were more common in patients with lower Hb values compared to those with higher values. Conversely, unprovoked VTE was more frequent in higher Hb quintiles.&lt;/p&gt;\u0000&lt;p&gt;The risk of adverse events declined progressively with increasing Hb values. In the lowest Hb quintile, 90-day rates of recurrent VTE, major bleeding, arterial ischemic events, and all-cause mortality were 2.2%, 4.1%, 0.5%, and 16%, respectively. In contrast, corresponding rates in the highest Hb quintile were 1.3%, 0.9%, 0.2%, and 3.2% (Table 1). Major bleeding and mortality rates were approximately five times higher in the lowest Hb quintile than in the highest, whereas VTE recurrence and arterial ischemic events were nearly twice as frequent. The major bleeding-to-VTE recurrence ratio was highest in the lowest quintile (1.86) and lowest in the highest quintile (0.49), indicating that bleeding risk outweighed thrombotic risk in anemic patients, whereas the opposite trend was observed in those with elevated Hb values.&lt;/p&gt;\u0000&lt;div&gt;\u0000&lt;header&gt;&lt;span&gt;TABLE 1. &lt;/span&gt;Outcomes during the first 3 months from VTE diagnosis, acco","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"26 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143940203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimal Depth of the Treatment Response Before Allogeneic Hematopoietic Transplantation for Chronic Myeloid Leukemia in Chronic Phase.","authors":"Yosuke Okada,Takeshi Kondo,Takuya Miyazaki,Yutaka Shimazu,Yosuke Minami,Fumihiko Ouchi,Shinichi Kako,Masatsugu Tanaka,Tetsuya Nishida,Shin-Ichiro Fujiwara,Naoyuki Uchida,Hirohisa Nakamae,Yuta Hasegawa,Keisuke Kataoka,Shingo Yano,Mamiko Sakata-Yanagimoto,Ayumu Ito,Jun Ishikawa,Yoshinobu Kanda,Koji Kawamura,Takahiro Fukuda,Yoshiko Atsuta,Takayoshi Tachibana","doi":"10.1002/ajh.27706","DOIUrl":"https://doi.org/10.1002/ajh.27706","url":null,"abstract":"","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"111 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143932773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Switching From Race-Based to Race-Neutral Spirometry Reference Equations in Children With Sickle Cell Anemia.","authors":"Jose A Mejias-Figueroa,Mark Rodeghier,Michael R DeBaun","doi":"10.1002/ajh.27704","DOIUrl":"https://doi.org/10.1002/ajh.27704","url":null,"abstract":"","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"3 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143932772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypoferremic Response to Chronic Inflammation Is Controlled via the Hemojuvelin/Hepcidin/Ferroportin Axis and Does Not Involve Hepcidin‐Independent Regulation of FpnmRNA","authors":"Siqi Liu, Sofiya Tsyplenkova, Carine Fillebeen, Kostas Pantopoulos","doi":"10.1002/ajh.27710","DOIUrl":"https://doi.org/10.1002/ajh.27710","url":null,"abstract":"The iron regulatory hormone hepcidin contributes to the pathogenesis of anemia of inflammation (AI) by inhibiting the iron exporter ferroportin in target cells, causing hypoferremia. Under acute inflammation, hepcidin induction requires hemojuvelin (Hjv), a bone morphogenetic protein co‐receptor, while <jats:italic>Fpn</jats:italic> mRNA is also suppressed in a hepcidin‐independent manner. However, it is unclear whether, during chronic inflammation, Hjv and hepcidin‐independent <jats:italic>Fpn</jats:italic> mRNA regulation are critical for hypoferremia and AI. To address these questions, wild type and <jats:italic>Hjv</jats:italic><jats:sup><jats:italic>−/−</jats:italic></jats:sup> mice, a model of hemochromatosis, were fed for 8 weeks an adenine‐rich diet to develop chronic kidney disease (CKD). Renal inflammation, accessed by increased <jats:italic>Il6</jats:italic> mRNA expression, did not differ among genotypes. Hjv disruption did not mitigate the severity of kidney injury but suppressed the inflammatory induction of liver hepcidin. CKD triggered hypoferremia and mild anemia in wild type mice; however, <jats:italic>Hjv</jats:italic><jats:sup><jats:italic>−/−</jats:italic></jats:sup> littermates maintained high serum iron and normal hemoglobin, consistent with a protective effect of Hjv/hepcidin deficiency. Notably, tissue <jats:italic>Fpn</jats:italic> mRNA levels were not affected by the inflammatory milieu of CKD. Following injection of wild type or <jats:italic>Hjv</jats:italic><jats:sup><jats:italic>−/−</jats:italic></jats:sup> mice with heat‐killed <jats:styled-content style=\"fixed-case\"><jats:italic>Brucella abortus</jats:italic></jats:styled-content>, <jats:italic>Fpn</jats:italic> mRNA was suppressed during the acute phase of inflammation but quickly recovered and persisted in the chronic phase. We conclude that Hjv deficiency reduces hepcidin levels and mitigates anemia in the CKD model, providing further support for pharmacological targeting of Hjv for the treatment of AI. Moreover, our data demonstrate that <jats:italic>Fpn</jats:italic> mRNA suppression only occurs under acute but not chronic inflammatory conditions and therefore cannot substantially contribute to AI pathogenesis.","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"94 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143930620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Allogeneic Hematopoietic Stem Cell Transplantation on Sickle Cell Retinopathy and Maculopathy: A Prospective, Observational Study","authors":"Rajani P. Brandsen, Elisabeth Dovern, Bart J. Biemond, Roselie M. H. Diederen, Erfan Nur","doi":"10.1002/ajh.27705","DOIUrl":"https://doi.org/10.1002/ajh.27705","url":null,"abstract":"&lt;p&gt;Sickle cell retinopathy (SCR) represents a significant ocular manifestation of sickle cell disease (SCD) that can dramatically impair visual acuity. SCR can be divided into non-proliferative SCR and proliferative SCR. Non-proliferative SCR involves abnormalities of the peripheral retina such as vascular occlusion without neovascularization, typical scarring (“black sunbursts”) and intraretinal hemorrhages (“salmon patches”). Proliferative SCR represents the more severe form of SCR, characterized by neovascularization. This can lead to vitreous hemorrhage or retinal detachment, which can temporarily or permanently impair visual acuity. In more recent years, modern imaging techniques such as spectral-domain optical coherence tomography (SD-OCT) and optical coherence tomography angiography (OCTA) have also revealed subclinical changes in the central part of the retina (the macula) in asymptomatic patients with SCD [&lt;span&gt;1&lt;/span&gt;]. These changes are referred to as sickle cell maculopathy (SCM) and include macular thinning, enlargement of the foveal avascular zone (FAZ) and lower vessel densities. Both SCR and SCM are progressive in nature and associated with increasing age [&lt;span&gt;2&lt;/span&gt;].&lt;/p&gt;\u0000&lt;p&gt;Allogeneic hematopoietic stem cell transplantation (HSCT) is the only established curative treatment option for patients with SCD. Improvements in non-myeloablative regimens have led to excellent disease-free and overall survival in transplanted adults with SCD, also in the setting of haploidentical HSCT [&lt;span&gt;3&lt;/span&gt;]. SCD-related organ damage is one of the main indications for HSCT, but data on long-term outcomes regarding the progression of organ complications is scarce [&lt;span&gt;4&lt;/span&gt;]. This is particularly true for adult patients, who frequently already have developed (sub-)clinical organ damage before HSCT.&lt;/p&gt;\u0000&lt;p&gt;Evidence concerning the behavior of SCR and SCM after HSCT is especially scarce. The only study on SCR after HSCT was conducted in children with SCD and did not include SCM [&lt;span&gt;5&lt;/span&gt;]. This leaves a significant gap in understanding how these conditions evolve in adults with SCD undergoing HSCT. We hypothesized that HSCT has the potential to stabilize pre-existing SCR and will prevent the development of new SCR in patients with SCD. Therefore, the aim of this study was to evaluate the natural course of SCR and SCM in an adult cohort of SCD patients undergoing HSCT.&lt;/p&gt;\u0000&lt;p&gt;In this prospective observational study in adults with SCD (HbSS, HbSC, HbSβ&lt;sup&gt;0&lt;/sup&gt; and HbSβ&lt;sup&gt;+&lt;/sup&gt; genotype), retinopathy and maculopathy were assessed before and at least 1 year post-transplant. All SCD patients undergoing non-myeloablative matched sibling donor (MSD) and haploidentical bone marrow transplantation were included [&lt;span&gt;3, 6&lt;/span&gt;]. Patients undergoing MSD transplantation received a 3-month preconditioning with azathioprine/hydroxyurea, followed by alemtuzumab (1 mg/kg) and 3 Gy total body irradiation (TBI) [&lt;span&gt;6&lt;/span&gt;]. The condit","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"27 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143926603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients: A Registry Study From the Société Francophone de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC).","authors":"Yves Chalandon,Raynier Devillier,Ariane Boumendil,Stephanie Nguyen,Claude-Eric Bulabois,Patrice Ceballos,Eolia Brissot,Marie-Thérèse Rubio,Hélène Labussière-Wallet,Johan Maertens,Patrice Chevallier,Natacha Maillard,Xavier Poiré,Cristina Castilla-Llorente,Yves Beguin,Jérôme Cornillon,Sébastien Maury,Tony Marchand,Etienne Daguindau,Jacques-Olivier Bay,Pascal Turlure,Magalie Joris,Anne-Lise Menard,Karin Bilger,Gaelle Guillerm,Sylvie François,Ali Bazarbachi,Sylvain Chantepie,Philippe Lewalle,Ambroise Marçais,Michael Loschi,Malek Benakli,Paul Chauvet,Edouard Forcade,Anne Huynh,Marie Robin,Stavroula Masouridi-Levrat","doi":"10.1002/ajh.27701","DOIUrl":"https://doi.org/10.1002/ajh.27701","url":null,"abstract":"There are very limited data regarding the outcomes of elderly patients with acute lymphoblastic leukemia (ALL) who undergo allogeneic hematopoietic stem cell transplantation (alloHSCT). A total of 316 ALL patients aged ≥ 60 years who underwent alloHSCT between 2010 to 2022 were identified in the SFGM-TC registry. The primary objective was to evaluate progression-free survival (PFS), non-relapse mortality (NRM), relapse incidence (RI), and graft-versus-host disease (GvHD)-free relapse-free survival (GRFS), as well as their risk factors. The median age was 63.8 years (range 60-75.8), 49.8% of patients had Philadelphia-positive B-ALL (Ph + ALL), and 70.9% were in first complete remission (CR1) at transplantation. The donor was an unrelated donor in 52.1%, a matched related donor (MRD) in 26.3%, and a haplo-identical donor in 17.7%. Reduced-intensity conditioning (RIC) was administered to 64.6% of patients, while total body irradiation (TBI) was used in 35.8%. The 3-year overall survival (OS) was 46% (95% CI 40%-53%). The 3-year PFS, NRM, RI, and GRFS were 41% (95% CI 35%-48%), 23% (95% CI 18%-28%), 36% (95% CI 31%-42%), and 30% (95% CI 25%-37%), respectively. Multivariable analyses confirmed poorer OS and PFS in patients with advanced disease, with an HR of 1.79 (95% CI 1.22-2.64), p = 0.0032. Additionally, the ALL subtype significantly impacted outcomes, with an HR of 1.99 (95% CI 1.42-2.79) for non-Ph + ALL. This study suggests that alloHSCT is a viable option for elderly ALL patients, as age itself did not impact outcomes. However, advanced disease and non-Ph + ALL were associated with significantly worse survival.","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"20 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143914855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing Outcomes in Relapsed and Refractory Multiple Myeloma: Personalized Approaches and Adverse Event Management","authors":"Eirini Katodritou, Evangelos Terpos, Suzanne Lentzsch, Shaji Kumar","doi":"10.1002/ajh.27646","DOIUrl":"https://doi.org/10.1002/ajh.27646","url":null,"abstract":"","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"60 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143905545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}